Dataset Information

Electrical power to run ventricular assist devices using the Free-range Resonant Electrical Energy Delivery system.

ABSTRACT: BACKGROUND:Models of power delivery within an intact organism have been limited to ionizing radiation and, to some extent, sound and magnetic waves for diagnostic purposes. Traditional electrical power delivery within the intact human body relies on implanted batteries that limit the amount and duration of delivered power. The efficiency of current battery technology limits the substantial demands required, such as continuous operation of an implantable artificial heart pump within a human body. METHODS:The fully implantable, miniaturized, Free-range Resonant Electrical Energy Delivery (FREE-D) system, compatible with any type of ventricular assist device (VAD), has been tested in a swine model (HVAD) for up to 3 hours. Key features of the system, the use of high-quality factor (Q) resonators together with an automatic tuning scheme, were tested over an extended operating range. Temperature changes of implanted components were measured to address safety and regulatory concerns of the FREE-D system in terms of specific absorption rate (SAR). RESULTS:Dynamic power delivery using the adaptive tuning technique kept the system operating at maximum efficiency, dramatically increasing the wireless power transfer within a 1-meter diameter. Temperature rise in the FREE-D system never exceeded the maximum allowable temperature deviation of 2°C (but remained below body temperature) for an implanted device within the trunk of the body at 10 cm (25% efficiency) and 50 cm (20% efficiency), with no failure episodes. CONCLUSIONS:The large operating range of FREE-D system extends the use of VAD for nearly all patients without being affected by the depth of the implanted pump. Our in-vivo results with the FREE-D system may offer a new perspective on quality of life for patients supported by implanted device.

SUBMITTER: Waters BH

PROVIDER: S-EPMC6240491 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Electrical power to run ventricular assist devices using the Free-range Resonant Electrical Energy Delivery system.

Waters Benjamin H BH Park Jiheum J Bouwmeester J Christopher JC Valdovinos John J Geirsson Arnar A Sample Alanson P AP Smith Joshua R JR Bonde Pramod P

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20180811 12

<h4>Background</h4>Models of power delivery within an intact organism have been limited to ionizing radiation and, to some extent, sound and magnetic waves for diagnostic purposes. Traditional electrical power delivery within the intact human body relies on implanted batteries that limit the amount and duration of delivered power. The efficiency of current battery technology limits the substantial demands required, such as continuous operation of an implantable artificial heart pump within a hum ...[more]

PMID: 30228086

Similar Datasets

Project description:BackgroundPercutaneous ventricular assist devices (PVADs) have been replacing intra-aortic balloon pumps for hemodynamic support during percutaneous coronary intervention (PCI), even though data supporting a benefit for hard clinical end points remain limited. We evaluated diffusion of PVADs across US markets and examined the association of market utilization of PVAD with mortality and cost.MethodsUsing the 2013 to 2019 Medicare data, we identified all patients aged ≥65 years who underwent PCI with either a PVAD or intra-aortic balloon pump. We used hospital referral region to define regional health care markets and categorized them in quartiles based on the proportional use of PVADs during PCI. Multilevel models were constructed to determine the association of patient, hospital, and market factors with utilization of PVADs and the association of PVAD utilization with 30-day mortality and cost.ResultsA total of 79 176 patients underwent PCI with either intra-aortic balloon pump (47 514 [60.0%]) or PVAD (31 662 [40.0%]). The proportion of PCI procedures with PVAD increased over time (17% in 2013 to 57% in 2019; P for trend, <0.001), such that PVADs overtook intra-aortic balloon pump for hemodynamic support during PCI in 2018. There was a large variation in PVAD utilization across markets (range, 0%-85%), which remained unchanged after adjustment of patient characteristics (median odds ratio, 2.05 [95% CI, 1.91-2.17]). The presence of acute myocardial infarction, cardiogenic shock, and emergent status was associated with a 45% to 50% lower odds of PVAD use suggesting that PVADs were less likely to be used in the sickest patients. Greater utilization of PVAD at the market level was not associated with lower risk mortality but was associated with higher cost.ConclusionsAlthough utilization of PVADs for PCI continues to increase, there is large variation in PVAD utilization across markets. Greater market utilization of PVADs was not associated with lower mortality but was associated with higher cost.

Dataset Information

Electrical power to run ventricular assist devices using the Free-range Resonant Electrical Energy Delivery system.

Publications

Electrical power to run ventricular assist devices using the Free-range Resonant Electrical Energy Delivery system.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets